These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 35431535)

  • 41. Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity.
    Prüβ BM
    Front Biosci (Landmark Ed); 2022 Feb; 27(2):65. PubMed ID: 35227008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
    Xia S; Wang L; Zhu Y; Lu L; Jiang S
    Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
    Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
    iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic.
    Rahman S; Hossain MJ; Nahar Z; Shahriar M; Bhuiyan MA; Islam MR
    Environ Health Insights; 2022; 16():11786302221129396. PubMed ID: 36299441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants.
    Chaki SP; Kahl-McDonagh MM; Neuman BW; Zuelke KA
    Microbiol Spectr; 2022 Jun; 10(3):e0066522. PubMed ID: 35638906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The mechanisms of immune response and evasion by the main SARS-CoV-2 variants.
    Chen Q; Zhang J; Wang P; Zhang Z
    iScience; 2022 Oct; 25(10):105044. PubMed ID: 36068846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic.
    Noor R
    Bull Natl Res Cent; 2022; 46(1):31. PubMed ID: 35194369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates.
    Sanders JW; Ewing D; Sundaram AK; Gamble CS; Blevins M; Liang Z; Sanders LA; Ornelles DA; Sun P; Lenart K; Feuerstein H; Loré K; Petrovsky N; Williams M; Porter KR
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.
    Wu D; Zhang Y; Tang L; Wang F; Ye Y; Ma C; Zheng H; Yu W; Cao L; Song Y; Reyimu A; Zhang X; Wang H; Nie Y; Lu M; Qi M; Li J; Wang R; Yang K; Wang C; Rodewald LE; Gao GF; An Z; Yin Z
    China CDC Wkly; 2022 Jan; 4(4):57-65. PubMed ID: 35186369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.
    Liang HY; Wu Y; Yau V; Yin HX; Lowe S; Bentley R; Ahmed MA; Zhao W; Sun C
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.